NASDAQ · QURE
Healthcare · Biotechnology
$24.83
Down-$0.47 (-1.86%)
Updated Nov 2, 2026, 7:03 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · QURE
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
QURE closed at $24.83 after 20 trading sessions, up 8.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $25.11 | $25.21 | $23.56 | $24.83 | 1.9M |
| Oct 29, 2026 | $24.86 | $25.99 | $24.60 | $25.30 | 1.71M |
| Oct 28, 2026 | $24.15 | $25.20 | $23.745 | $24.97 | 1.19M |
| Oct 27, 2026 | $21.76 | $24.31 | $21.45 | $24.28 | 1.57M |
| Oct 26, 2026 | $22.50 | $22.606 | $21.52 | $21.65 | 988.7K |
| Oct 23, 2026 | $23.11 | $23.275 | $22.04 | $22.43 | 884.48K |
| Oct 22, 2026 | $23.40 | $23.89 | $22.78 | $23.11 | 1.55M |
| Oct 21, 2026 | $23.05 | $23.17 | $22.32 | $22.69 | 1.12M |
| Oct 20, 2026 | $22.20 | $22.8199 | $21.735 | $22.715 | 1.42M |
| Oct 19, 2026 | $22.13 | $22.45 | $21.6652 | $22.20 | 1.37M |
| Oct 16, 2026 | $22.50 | $22.68 | $21.70 | $21.78 | 1.29M |
| Oct 15, 2026 | $21.94 | $22.56 | $20.76 | $22.52 | 1.61M |
| Oct 14, 2026 | $21.00 | $21.75 | $20.33 | $20.97 | 3.33M |
| Oct 13, 2026 | $21.66 | $21.66 | $20.75 | $21.28 | 2.49M |
| Oct 12, 2026 | $22.38 | $22.593 | $21.49 | $21.84 | 1.41M |
| Oct 9, 2026 | $22.59 | $23.00 | $22.23 | $22.59 | 2.05M |
| Oct 8, 2026 | $22.92 | $23.0032 | $21.70 | $22.54 | 1.82M |
| Oct 7, 2026 | $22.96 | $23.30 | $22.62 | $23.14 | 1.78M |
| Oct 6, 2026 | $23.02 | $23.84 | $21.20 | $23.06 | 2.82M |
| Oct 5, 2026 | $22.28 | $23.24 | $21.37 | $22.80 | 3.04M |
The latest Smart Investors Daily articles mentioning QURE.
Company
Market Activity
Research & News
QURE research
Company profile and research snapshot.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Barclays | Equal-Weight | — |
| Oct 2, 2026 | RBC Capital | Outperform | — |
| Sep 30, 2026 | Goldman Sachs | Neutral | — |
| Sep 2, 2026 | William Blair | Outperform | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Oct 15, 2026
UniQure (QURE) stock is a Speculative Buy: $47 price target (115% upside). FDA accelerated review for Huntingtonâs gene therapy; decision due ~Nov 1. Read the full analysis here.
Yahoo · Oct 7, 2026
uniQure N.V. recently reported additional 36- and 48-month Phase I/II data for its Huntington’s disease gene therapy ifezuntirgene inilparvovec, showing continued slowing of disease progression versus matched external controls and supporting its previously submitted accelerated approval BLA. The update highlights durable, dose-dependent effects across key clinical measures and a generally manageable safety profile, reinforcing ifezuntirgene inilparvovec’s potential as a first-in-class,...
Benzinga · Oct 5, 2026
Barclays analyst Eliana Merle downgrades uniQure (NASDAQ:QURE) from Overweight to Equal-Weight and lowers the price target from $60 to $28.
Benzinga · Oct 2, 2026
RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the price target from $65 to $48.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QURE.
